Senseonics Holdings, Inc.
Senseonics Holdings, Inc. (Nasdaq: SENS) is a medical technology company that develops and commercializes Eversense implantable continuous glucose monitoring (CGM) systems for people with diabetes. The system combines a sensor placed under the skin by a healthcare provider, a removable and rechargeable smart… From the company’s description.
Over the twelve months to Jun 30, 2026, Senseonics Holdings, Inc. reported revenue of $48.55M, up 90.6% from a year earlier, and a net loss of $109.39M. Its operating margin was −223.2%, and operations used $95.94M in cash. In fiscal 2025, it reported revenue of $35.26M, up 56.9% from fiscal 2024, and a net loss of $69.11M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Senseonics Holdings, Inc. does
In the company’s own words
Senseonics Holdings, Inc. (Nasdaq: SENS) is a medical technology company that develops and commercializes Eversense implantable continuous glucose monitoring (CGM) systems for people with diabetes. The system combines a sensor placed under the skin by a healthcare provider, a removable and rechargeable smart transmitter, and a mobile app that provides glucose readings, trends and alerts. Eversense 365 is designed for use for up to one year, while Eversense E3 is designed for up to six months. The company sells through distributors and strategic fulfillment partners and also uses a consignment model with healthcare professionals; its products reach patients through prescriptions and are reimbursed by insurance payors or government programs. In January 2026, Senseonics assumed U.S. commercial responsibility for Eversense from Ascensia and became entitled to all product revenue in the European Territories, where Ascensia’s distribution rights are non-exclusive. The company also develops Gemini and Freedom product variations. Its principal product brand is Eversense.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- GERMANTOWN, MD
- Fiscal year end
- December
- CIK
- 1616543
- SIC
- 3823
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Senseonics Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Senseonics Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Senseonics Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Senseonics Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Senseonics Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”